BACKGROUND: Conventional clinicopathologic risk factors have failed to accurately predict the prognosis of patients with bladder cancer (BC). OBJECTIVE: To evaluate karyopherin-α2 (KPNA2) expression as a progression marker in patients with non-muscle-invasive BC (NMIBC) treated by conservative methods and as a prognostic marker in patients with invasive BC undergoing radical cystectomy (RC). DESIGN, SETTING, AND PARTICIPANTS: Two different tissue microarrays were constructed, one with 234 primary Ta/T1 tumours from patients treated by transurethral resection of the bladder and one with 377 tumours from RC patients. INTERVENTION: KPNA2 expression based on immunohistochemistry. MEASUREMENTS: Risk of progression of Ta/T1 patients to muscle-invasive BC was estimated in clinical follow-up to progression or a minimum of 53 mo. Risk of recurrent disease and death following RC was estimated in clinical follow-up of a minimum of 24 mo in patients alive. RESULTS AND LIMITATIONS: A high KPNA2 expression in Ta/T1 patients was significantly correlated with a higher risk of progression that was independent of conventional risk factors in multivariate analysis. In patients undergoing RC, a high KPNA2 expression was an independent predictor of poor prognosis. A high KPNA2 expression was correlated with a higher risk of visceral metastasis rather than lymphatic spread. CONCLUSIONS: KPNA2 expression is a marker for progression of NMIBC and a prognostic marker in patients undergoing RC.
BACKGROUND: Conventional clinicopathologic risk factors have failed to accurately predict the prognosis of patients with bladder cancer (BC). OBJECTIVE: To evaluate karyopherin-α2 (KPNA2) expression as a progression marker in patients with non-muscle-invasive BC (NMIBC) treated by conservative methods and as a prognostic marker in patients with invasive BC undergoing radical cystectomy (RC). DESIGN, SETTING, AND PARTICIPANTS: Two different tissue microarrays were constructed, one with 234 primary Ta/T1 tumours from patients treated by transurethral resection of the bladder and one with 377 tumours from RC patients. INTERVENTION: KPNA2 expression based on immunohistochemistry. MEASUREMENTS: Risk of progression of Ta/T1 patients to muscle-invasive BC was estimated in clinical follow-up to progression or a minimum of 53 mo. Risk of recurrent disease and death following RC was estimated in clinical follow-up of a minimum of 24 mo in patients alive. RESULTS AND LIMITATIONS: A high KPNA2 expression in Ta/T1 patients was significantly correlated with a higher risk of progression that was independent of conventional risk factors in multivariate analysis. In patients undergoing RC, a high KPNA2 expression was an independent predictor of poor prognosis. A high KPNA2 expression was correlated with a higher risk of visceral metastasis rather than lymphatic spread. CONCLUSIONS:KPNA2 expression is a marker for progression of NMIBC and a prognostic marker in patients undergoing RC.
Authors: Alana Lelo; Frederik Prip; Brent T Harris; David Solomon; Deborah L Berry; Krysta Chaldekas; Anagha Kumar; Jeffry Simko; Jørgen Bjerggaard Jensen; Pritish Bhattacharyya; Ciaran Mannion; Jung-Sik Kim; George Philips; Lars Dyrskjøt; Todd Waldman Journal: Clin Cancer Res Date: 2018-06-28 Impact factor: 12.531
Authors: Bassel G Bachir; Armen G Aprikian; Yves Fradet; Joseph L Chin; Jonathan Izawa; Ricardo Rendon; Eric Estey; Adrian Fairey; Ilias Cagiannos; Louis Lacombe; Jean-Baptiste Lattouf; David Bell; Fred Saad; Darrel Drachenberg; Wassim Kassouf Journal: Can Urol Assoc J Date: 2013 Nov-Dec Impact factor: 1.862
Authors: Pia B Erben; Kathrin Brunner; Markus Hecht; Marlen Haderlein; Maike Büttner-Herold; Abbas Agaimy; Rainer Fietkau; Arndt Hartmann; Luitpold V Distel Journal: Int J Clin Exp Pathol Date: 2015-12-01